BACKGROUND: The lifespan of patients with cystic fibrosis (CF) is increasing significantly. The objective of this international pilot study was to study the characteristics of these long-term survivors. METHODS: Four centres with large CF clinics from London (UK), Minneapolis (USA), Toronto (Canada) and Verona (Italy) identified 366 patients who had survived 40 years and longer. RESULTS: At all centres males survived longer than females. There were more pancreatic sufficient patients in Verona (60%) and Toronto (40%) than in London (16%) and Minneapolis (21%). The percentage of DeltaF508 homozygous patients varied between 47% in London and 45% in Minneapolis to only 26% in Toronto and 9% in Verona. Average FEV(1) and BMI values of the surviving population appeared to stabilise after 40 years of age. FEV(1) was on average 12% higher in patients who were pancreatic sufficient (p > 0.0001). There was no difference in survival between the centres. The overall median survival after the age of 40 was 13 years. The estimated annual death rate was approximately 3.4% from the age of 40-60 years. CONCLUSIONS: Significant numbers of patients are now surviving to 40 years or more, and it is hoped that an in-depth study of these patients may identify the factors contributing to longer survival.
BACKGROUND: The lifespan of patients with cystic fibrosis (CF) is increasing significantly. The objective of this international pilot study was to study the characteristics of these long-term survivors. METHODS: Four centres with large CF clinics from London (UK), Minneapolis (USA), Toronto (Canada) and Verona (Italy) identified 366 patients who had survived 40 years and longer. RESULTS: At all centres males survived longer than females. There were more pancreatic sufficient patients in Verona (60%) and Toronto (40%) than in London (16%) and Minneapolis (21%). The percentage of DeltaF508 homozygous patients varied between 47% in London and 45% in Minneapolis to only 26% in Toronto and 9% in Verona. Average FEV(1) and BMI values of the surviving population appeared to stabilise after 40 years of age. FEV(1) was on average 12% higher in patients who were pancreatic sufficient (p > 0.0001). There was no difference in survival between the centres. The overall median survival after the age of 40 was 13 years. The estimated annual death rate was approximately 3.4% from the age of 40-60 years. CONCLUSIONS: Significant numbers of patients are now surviving to 40 years or more, and it is hoped that an in-depth study of these patients may identify the factors contributing to longer survival.
Authors: Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag Journal: Am J Respir Crit Care Med Date: 2010-05-06 Impact factor: 21.405
Authors: Megumi J Okumura; Thida Ong; Diana Dawson; Dennis Nielson; Nancy Lewis; Martha Richards; Claire D Brindis; Mary Ellen Kleinhenz Journal: BMJ Qual Saf Date: 2014-01-10 Impact factor: 7.035
Authors: Franziska A Stressmann; Geraint B Rogers; Erich R Klem; Andrew K Lilley; Scott H Donaldson; Thomas W Daniels; Mary P Carroll; Nilesh Patel; Benjamin Forbes; Richard C Boucher; Matthew C Wolfgang; Kenneth D Bruce Journal: J Clin Microbiol Date: 2010-11-10 Impact factor: 5.948
Authors: Danieli Barino Salinas; Colleen Azen; Suzanne Young; Thomas G Keens; Martin Kharrazi; Richard B Parad Journal: Genet Test Mol Biomarkers Date: 2016-07-22
Authors: Christopher H Goss; Jenna Sykes; Sanja Stanojevic; Bruce Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Bradley S Quon; Anne L Stephenson Journal: Am J Respir Crit Care Med Date: 2018-03-15 Impact factor: 30.528
Authors: Anthony A Fodor; Erich R Klem; Deirdre F Gilpin; J Stuart Elborn; Richard C Boucher; Michael M Tunney; Matthew C Wolfgang Journal: PLoS One Date: 2012-09-26 Impact factor: 3.240